Starling Oncology, Inc. is a value-based oncology company that provides outpatient cancer care, medical oncology, radiation oncology, and hematology services. Founded in 2007 as The Oncology Institute, Inc., the company operates a network of affiliated physician-owned clinics and contracted independent providers across five states in the United States. Its business lines include fee-for-service patient services, value-based capitated and gain/loss sharing contracts with managed care organizations, specialty and retail pharmacy services, and clinical trial management through its subsidiary TOI Clinical Research, LLC. The company serves commercial and government payors and partners with risk-bearing entities to manage oncology populations, including a 2025 profit-sharing arrangement with Helios Clinical Research. Starling Oncology offers comprehensive care including infusion therapy, blood transfusions, palliative care, and access to targeted therapies, immunotherapy, and precision medicine.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Care Facilities Homepage starlingoncology.com
Sector Healthcare IR page investors.starlingoncology.com
Tags
oncology, radiation oncology, medical oncology, value-based care, specialty pharmacy, clinical trials, palliative care, hematology, infusion therapy, blood transfusion, The Oncology Institute, TOI, TOI PCs, TOI Clinical Research LLC, TCR, Helios Clinical Research
Press page —

Metrics

Valuation  
Market cap $ 372.267M
Market cap (USD) $ 372.267M
P/E -13.52
PEG —
P/BV -9.97
P/S 0.60
P/OCF 16.12
P/FCF 19.77
Dividend yield —
Turnover / mcap —
Returns  
ROE 385.5%
ROI -98.3%
ROIC -43.9%
Profit margin -12.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 10
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 502.729M 393.412M 324.239M 252.483M 203.003M 187.515M
Net profit -60.606M -64.663M -83.068M 152K -10.927M -14.322M
Free cash flow -27.787M -30.327M -40.882M -67.285M -35.527M -686K

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 3.56 0.31 2.04 1.65 9.75 —
Price performance 12m 10.52 -0.85 0.24 -0.83 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 17.1M 20M 39.8M 42.4M 48.3M 59M
↳ YoY growth +16.7% +99.0% +6.4% +14.1% +22.1%
↳ 5y CAGR +28.0%
Borrowings, current (USD) — 5.37M 183,000 0.00 — — —
Borrowings, non-current (USD) — 6.56M 0.00 80.6M 86.8M 93.1M 77.4M
Lease liabilities (USD) — — 0.00 27.8M 33M 30.1M 26.4M
Cash and deposits (USD) 25,000 900,000 115M 14M 33.5M 49.7M 33.6M
Intangible assets (USD) — 19.5M 18.2M 18M 17.9M 14.8M 11M
Right-of-use assets (USD) — — 0.00 24.5M 29.2M 25.8M 22.4M
Net debt (borrowings + leases - cash) (USD) — 5.93M -115M 94.4M 86.3M 73.6M 70.2M
Cash flow detail
Operating cash flow (USD) — -582,527 -32.7M -61.8M -36.3M -26.5M -24.6M
Purchases of property, plant and equipment (USD) — -1.19M -2.85M -5.53M -4.57M -3.79M -3.2M
Purchases of intangible assets (USD) — 0.00 -200,000 0.00 — — —
Change in receivables (cash effect) (USD) — -6.76M -2.2M -20.3M -4.56M -5.98M -12.3M
Change in inventories (cash effect) (USD) — -465,000 -1.84M -1.73M -4.39M 3.64M -6.84M
Change in payables (cash effect) (USD) — 3.76M 2.92M -6.19M 5.06M 9.22M 19.6M
Share buybacks (cash effect) (USD) — — 0.00 -9M -1.02M 0.00 —
Interest paid (cash effect) (USD) — -227,000 -275,000 -224,000 -4.51M -4.5M -3.91M
Income taxes paid (cash effect) (USD) — -207,000 -1.73M -150,000 -403,000 0.00 —
Share-based compensation (USD) — 151,000 24.5M 27.7M 17.8M 11.2M 4.55M
Operating cash flow before change in receivables (USD) — 7.27M -30.5M -41.5M -31.8M -20.6M -12.3M
Free cash flow (OCF - PPE - intangibles) (USD) — -686,000 -35.7M -67.3M -40.9M -30.3M -27.8M
Income detail
Provision for credit losses (USD) — 4.23M -417,000 476,000 2.02M 0.00 0.00
Credit cost ratio (credit losses / average receivables) (%) — — 2.2% 1.6% 4.9% 0.0% 0.0%
Reported May 8, 2020 Mar 11, 2022 Mar 16, 2023 Mar 16, 2023 Mar 28, 2024 Mar 26, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Starling Oncology, Inc. — Regulation FD Disclosure Bull 0 Bear 0 Routine

Starling Oncology, Inc. (the “Company”) has prepared an investor presentation (the “Investor Presentation”) to use in meetings with investors. A copy of the Investor Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Starling Oncology, Inc. — Regulation FD Disclosure Bull 0 Bear 0 Routine

Starling Oncology, Inc. (the “Company”) has prepared an updated investor presentation (the “Investor Presentation”) to use in meetings with investors. A copy of the Investor Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K/A and supersedes the investor presentation furnished as Exhibit 99.1 to the Original Report.

CERRITOS, Calif., November 5, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended September 30, 2026 and updated it's full-year 2026 guidance.

Recent Operational Highlights

• Specialty Pharmacy Revenue was $109 million, up 44 percent year over year, and gross margin was 24 percent. Continued increase in the capture rate of fills written by Starling physicians was the primary contributor to year-over-year revenue growth in the specialty pharmacy.

• Capitated revenue grew 40 percent year over year in the third quarter, and our medical loss ratio, or MLR, improved sequentially to 81.0 percent, compared to 85.5 percent in the second quarter and 67.8% in the prior year period.

• Starling Nexus, our proprietary utilization management portal, is now live for our network providers who practice in all markets where we have delegated capitation arrangements and is the interface through which prior authorizations are submitted for UM review.

Prompts

Starling Oncology, Inc. (ticker STLN), listed in United States.

Company History

Date Change Detail
Aug 6, 2026 Renamed ONCOLOGY INSTITUTE, INC. → STARLING ONCOLOGY, INC.
Aug 30, 2021 Renamed DFP HEALTHCARE ACQUISITIONS CORP. → ONCOLOGY INSTITUTE, INC.
— Former tickers TOIIW, TOI

ETFs Holding Starling Oncology, Inc.

ETF Weight in ETF Shares Market value As of
VFMO 0.10% 316,217 $ 1.869M Aug 31, 2026
FSEG 0.02% 158 $ 857.94 Jun 30, 2026
RESM 0.01% 100 $ 543.00 Jun 30, 2026
FESM 0.01% 53,447 $ 290.217K Jun 30, 2026
MSSM 0.00% 5,862 $ 34.644K Aug 31, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
STLN canonical Common share — US nasdaq 3.65 USD 2026-11-09
TOIIW Warrant — US nasdaq — —
STLNW Warrant — US nasdaq 0.05 USD 2026-09-30